HUTCHMED to Announce 2025 Half-Year Financial Results
HUTCHMED (NASDAQ/AIM/HKEX: HCM) has scheduled the announcement of its 2025 half-year financial results for Thursday, August 7, 2025 at 7:00 am EDT. The company will host two separate webcasts for analysts and investors:
The English presentation will take place on August 7, 2025, at 8:00 am EDT, while the Chinese (Putonghua) presentation will be held on August 8, 2025, at 8:30 am HKT. Both webcasts will be accessible through the company's website, with presentation materials available for download before the events and replays available afterward.
HUTCHMED (NASDAQ/AIM/HKEX: HCM) ha programmato l'annuncio dei risultati finanziari semestrali del 2025 per giovedì 7 agosto 2025 alle 7:00 EDT. L'azienda terrà due webcast separati per analisti e investitori:
La presentazione in inglese si svolgerà il 7 agosto 2025 alle 8:00 EDT, mentre la presentazione in cinese (Putonghua) avrà luogo l'8 agosto 2025 alle 8:30 HKT. Entrambi i webcast saranno accessibili tramite il sito web della società, con i materiali della presentazione disponibili per il download prima degli eventi e le registrazioni disponibili successivamente.
HUTCHMED (NASDAQ/AIM/HKEX: HCM) ha programado el anuncio de sus resultados financieros semestrales de 2025 para el jueves 7 de agosto de 2025 a las 7:00 am EDT. La compañía realizará dos transmisiones web separadas para analistas e inversores:
La presentación en inglés se llevará a cabo el 7 de agosto de 2025 a las 8:00 am EDT, mientras que la presentación en chino (Putonghua) será el 8 de agosto de 2025 a las 8:30 am HKT. Ambas transmisiones estarán disponibles a través del sitio web de la empresa, con materiales de presentación descargables antes de los eventos y repeticiones accesibles posteriormente.
HUTCHMED (NASDAQ/AIM/HKEX: HCM)� 2025� 반기 재무 결과 발표� 2025� 8� 7� 목요� 오전 7� EDT� 예정하고 있습니다. 회사� 애널리스� � 투자자를 위해 � 차례� 별도 웹캐스트� 진행� 예정입니�:
영어 발표� 2025� 8� 7� 오전 8� EDT� 진행되며, 중국�(표준�) 발표� 2025� 8� 8� 오전 8� 30� HKT� 개최됩니�. � 웹캐스트 모두 회사 웹사이트� 통해 접속 가능하�, 발표 자료� 행사 � 다운로드� � 있고 이후에는 다시보기 서비스도 제공됩니�.
HUTCHMED (NASDAQ/AIM/HKEX : HCM) a programmé l'annonce de ses résultats financiers semestriels 2025 pour le jeudi 7 août 2025 à 7h00 EDT. La société organisera deux webinaires distincts pour les analystes et investisseurs :
La présentation en anglais aura lieu le 7 août 2025 à 8h00 EDT, tandis que la présentation en chinois (putonghua) se tiendra le 8 août 2025 à 8h30 HKT. Les deux webinaires seront accessibles via le site internet de la société, avec les documents de présentation disponibles en téléchargement avant les événements et les rediffusions accessibles ensuite.
HUTCHMED (NASDAQ/AIM/HKEX: HCM) hat die Bekanntgabe seiner Halbjahresfinanzergebnisse 2025 für Donnerstag, den 7. August 2025 um 7:00 Uhr EDT geplant. Das Unternehmen wird zwei separate Webcasts für Analysten und Investoren veranstalten:
Die englische Präsentation findet am 7. August 2025 um 8:00 Uhr EDT statt, während die chinesische (Putonghua) Präsentation am 8. August 2025 um 8:30 Uhr HKT abgehalten wird. Beide Webcasts sind über die Website des Unternehmens zugänglich, mit Präsentationsmaterialien, die vor den Veranstaltungen zum Download bereitstehen, sowie Aufzeichnungen, die danach verfügbar sind.
- None.
- None.
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., July 03, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“�) (Nasdaq/AIM: HCM; HKEX:13) will announce its interim results for the six months ended June 30, 2025 on Thursday, August 7, 2025 at 7:00 am Eastern Daylight Time (EDT) / 12:00 noon British Summer Time (BST) / 7:00 pm Hong Kong Time (HKT).
HUTCHMED management will host two webcast presentations for analysts and investors to discuss the interim results, followed by Q&A sessions. The English webcast will be held on Thursday, August 7, 2025, at 8:00 am EDT (1:00 pm BST / 8:00 pm HKT). The Chinese (Putonghua) webcast will be held at 8:30 am HKT / 1:30 am BST on Friday, August 8, 2025 (8:30 pm EDT on Thursday, August 7, 2025).
Both webcasts will be available live via the company website at . The presentation will be available to download shortly before the webcast begins. A replay will also be available on the website shortly after the event.
About HUTCHMED
HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: or follow us on .
CONTACTS
Investor Enquiries | +85221218200 / [email protected] |
Media Enquiries | |
FTIConsulting � | +442037271030/ [email protected] |
Ben Atwell / Alex Shaw | +447771913902(Mobile)/ +447779545055(Mobile) |
Brunswick � Zhou Yi | +85297836894(Mobile)/ [email protected] |
Panmure Liberum | Nominated Advisor and Joint Broker |
Atholl Tweedie/ Emma Earl/ Rupert Dearden | +442078862500 |
Cavendish | Joint Broker |
Geoff Nash/ Nigel Birks | +442072200500 |
Deutsche Numis | Joint Broker |
Freddie Barnfield / Jeffrey Wong / Duncan Monteith | +44 20 7260 1000 |
